nach oben

Tumor Biology

Erschienen in:

01.04.2014 | Research Article

The Arg188His polymorphism in the XRCC2 gene and the risk of cancer

verfasst von: Yonggang Zhang, Haichuan Wang, Yuanling Peng, Yuqi Liu, Tianyuan Xiong, Pei Xue, Liang Du

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The Arg188His polymorphism in the XRCC2 gene has been suggested as a risk factor for cancer with inconclusive results. The aim of the current study is to investigate the association between the polymorphism with of cancer by meta-analysis. A total of 33 case–control studies from 27 publications were included for data analyses. The results suggested that the Arg188His polymorphism was not associated with increased/decreased risk of cancer in total analysis (Arg/His+His/His vs. Arg/Arg: OR = 0.98, 95 % CI = 0.91–1.06). In the subgroup analysis by ethnicity, no statistical significant association was found in Europeans. In the subgroup analysis by cancer types, statistical significant association was found in ovarian cancer but not in other cancers. The current meta-analysis indicated that the Arg188His polymorphism in the XRCC2 gene might be a risk factor for ovarian cancer. In the future, more large-scale case–control studies are needed to validate our results.

Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet. 2002;11(12):1399–407.PubMedCrossRef

Curtin K, Lin WY, George R, Katory M, Shorto J, Cannon-Albright LA, et al. Genetic variants in XRCC2: new insights into colorectal cancer tumorigenesis. Cancer Epidemiol Biomark Prev. 2009;18(9):2476–84. doi:10.1158/1055-9965.EPI-09-0187.CrossRef

Garcia-Closas M, Egan KM, Newcomb PA, Brinton LA, Titus-Ernstoff L, Chanock S, et al. Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet. 2006;119(4):376–88. doi:10.1007/s00439-006-0135-z.PubMedCrossRef

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.PubMedCrossRef

Benhamou S, Tuimala J, Bouchardy C, Dayer P, Sarasin A, Hirvonen A. DNA repair gene XRCC2 and XRCC3 polymorphisms and susceptibility to cancers of the upper aerodigestive tract. Int J Cancer J int Cancer. 2004;112(5):901–4. doi:10.1002/ijc.20474.CrossRef

Park DJ, Lesueur F, Nguyen-Dumont T, Pertesi M, Odefrey F, Hammet F, et al. Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet. 2012;90(4):734–9. doi:10.1016/j.ajhg.2012.02.027.PubMedCentralPubMedCrossRef

Perez LO, Crivaro A, Barbisan G, Poleri L, Golijow CD. XRCC2 R188H (rs3218536), XRCC3 T241M (rs861539) and R243H (rs77381814) single nucleotide polymorphisms in cervical cancer risk. Pathol Oncol Res. 2013;19(3):553–8. doi:10.1007/s12253-013-9616-2.PubMedCrossRef

Pooley KA, Baynes C, Driver KE, Tyrer J, Azzato EM, Pharoah PD, et al. Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk. Cancer Epidemiol Biomark Prev. 2008;17(12):3482–9. doi:10.1158/1055-9965.EPI-08-0594.CrossRef

Han J, Hankinson SE, Ranu H, De Vivo I, Hunter DJ. Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses’ Health Study. Carcinogenesis. 2004;25(2):189–95. doi:10.1093/carcin/bgh002.PubMedCrossRef

10.

Krupa R, Sliwinski T, Wisniewska-Jarosinska M, Chojnacki J, Wasylecka M, Dziki L, et al. Polymorphisms in RAD51, XRCC2 and XRCC3 genes of the homologous recombination repair in colorectal cancer—a case control study. Mol Biol Rep. 2011;38(4):2849–54. doi:10.1007/s11033-010-0430-6.PubMedCentralPubMedCrossRef

11.

Matullo G, Guarrera S, Sacerdote C, Polidoro S, Davico L, Gamberini S, et al. Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case–control study. Cancer Epidemiol Biomark Prev. 2005;14(11 Pt 1):2569–78. doi:10.1158/1055-9965.EPI-05-0189.CrossRef

12.

Zhang Y, He J, Deng Y, Zhang J, Li X, Xiang Z, et al. The insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme gene and cancer risk: a meta-analysis. BMC Med Genet. 2011;12:159. doi:10.1186/1471-2350-12-159.PubMedCentralPubMedCrossRef

13.

Auranen A, Song H, Waterfall C, Dicioccio RA, Kuschel B, Kjaer SK, et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer J Int Cancer. 2005;117(4):611–8. doi:10.1002/ijc.21047.CrossRef

14.

Beesley J, Jordan SJ, Spurdle AB, Song H, Ramus SJ, Kjaer SK, et al. Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomark Prev. 2007;16(12):2557–65. doi:10.1158/1055-9965.EPI-07-0542.CrossRef

15.

Millikan RC, Player JS, Decotret AR, Tse CK, Keku T. Polymorphisms in DNA repair genes, medical exposure to ionizing radiation, and breast cancer risk. Cancer Epidemiol Biomark Prev. 2005;14(10):2326–34. doi:10.1158/1055-9965.EPI-05-0186.CrossRef

16.

Webb PM, Hopper JL, Newman B, Chen X, Kelemen L, Giles GG, et al. Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol Biomark Prev. 2005;14(2):319–23. doi:10.1158/1055-9965.EPI-04-0335.CrossRef

17.

Bastos HN, Antao MR, Silva SN, Azevedo AP, Manita I, Teixeira V, et al. Association of polymorphisms in genes of the homologous recombination DNA repair pathway and thyroid cancer risk. Thyroid. 2009;19(10):1067–75. doi:10.1089/thy.2009.0099.PubMedCrossRef

18.

Brooks J, Shore RE, Zeleniuch-Jacquotte A, Currie D, Afanasyeva Y, Koenig KL, et al. Polymorphisms in RAD51, XRCC2, and XRCC3 are not related to breast cancer risk. Cancer Epidemiol Biomark Prev. 2008;17(4):1016–9. doi:10.1158/1055-9965.EPI-08-0065.CrossRef

19.

Fayaz S, Fard-Esfahani P, Fard-Esfahani A, Mostafavi E, Meshkani R, Mirmiranpour H, et al. Assessment of genetic mutations in the XRCC2 coding region by high resolution melting curve analysis and the risk of differentiated thyroid carcinoma in Iran. Genet Mol Biol. 2012;35(1):32–7.PubMedCentralPubMedCrossRef

20.

Figueroa JD, Malats N, Rothman N, Real FX, Silverman D, Kogevinas M, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis. 2007;28(8):1788–93. doi:10.1093/carcin/bgm132.PubMedCrossRef

21.

Garcia-Quispes WA, Perez-Machado G, Akdi A, Pastor S, Galofre P, Biarnes F, et al. Association studies of OGG1, XRCC1, XRCC2 and XRCC3 polymorphisms with differentiated thyroid cancer. Mutat Res. 2011;709–710:67–72. doi:10.1016/j.mrfmmm.2011.03.003.PubMedCrossRef

22.

Han J, Colditz GA, Samson LD, Hunter DJ. Polymorphisms in DNA double-strand break repair genes and skin cancer risk. Cancer Res. 2004;64(9):3009–13.PubMedCrossRef

23.

Han J, Hankinson SE, Hunter DJ, De Vivo I. Genetic variations in XRCC2 and XRCC3 are not associated with endometrial cancer risk. Cancer Epidemiol Biomark Prev. 2004;13(2):330–1.CrossRef

24.

Jiao L, Hassan MM, Bondy ML, Wolff RA, Evans DB, Abbruzzese JL, et al. XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. Am J Gastroenterol. 2008;103(2):360–7. doi:10.1111/j.1572-0241.2007.01615.x.PubMedCentralPubMedCrossRef

25.

Rafii S, O’Regan P, Xinarianos G, Azmy I, Stephenson T, Reed M, et al. A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Hum Mol Genet. 2002;11(12):1433–8.PubMedCrossRef

26.

Rajaraman P, Hutchinson A, Wichner S, Black PM, Fine HA, Loeffler JS, et al. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol. 2010;12(1):37–48.PubMedCentralPubMedCrossRef

27.

Romanowicz-Makowska H, Smolarz B, Gajecka M, Kiwerska K, Rydzanicz M, Kaczmarczyk D, et al. Polymorphism of the DNA repair genes RAD51 and XRCC2 in smoking- and drinking-related laryngeal cancer in a Polish population. Arch Med Sci. 2012;8(6):1065–75. doi:10.5114/aoms.2012.32417.PubMedCentralPubMedCrossRef

28.

Romanowicz-Makowska H, Smolarz B, Zadrozny M, Westfal B, Baszczynski J, Polac I, et al. Single nucleotide polymorphisms in the homologous recombination repair genes and breast cancer risk in Polish women. Tohoku J Exp Med. 2011;224(3):201–8.PubMedCrossRef

29.

Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis. 2006;27(3):560–7. doi:10.1093/carcin/bgi232.PubMedCrossRef

30.

Romanowicz H, Smolarz B, Baszczynski J, Zadrozny M, Kulig A. Genetics polymorphism in DNA repair genes by base excision repair pathway (XRCC1) and homologous recombination (XRCC2 and RAD51) and the risk of breast carcinoma in the Polish population. Pol J Pathol. 2010;61(4):206–12.PubMed

31.

Romanowicz-Makowska H, Smolarz B, Zadrozny M, Westfa B, Baszczynski J, Kokolaszwili G, et al. The association between polymorphisms of the RAD51-G135C, XRCC2-Arg188His and XRCC3-Thr241Met genes and clinico-pathologic features in breast cancer in Poland. Eur J Gynaecol Oncol. 2012;33(2):145–50.PubMed

Titel: The Arg188His polymorphism in the XRCC2 gene and the risk of cancer
verfasst von: Yonggang Zhang
Haichuan Wang
Yuanling Peng
Yuqi Liu
Tianyuan Xiong
Pei Xue
Liang Du
Publikationsdatum: 01.04.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1468-6

Springer Medizin

The Arg188His polymorphism in the XRCC2 gene and the risk of cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis

Association between the CYP1A1 A2455G polymorphism and risk of cancer: evidence from 272 case–control studies

Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients

Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis

Truncation of inhibitor of growth family protein 5 effectively induces senescence, but not apoptosis in human tongue squamous cell carcinoma cell line

Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie